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AbstrAct
Personalized medicine is an extension of traditional medicine is based on a highly individual approach to each 
patient. One of the most important tools that allow this approach is targeted therapy. It focuses mainly on 
blocking cancer cell’s proliferation and angiogenesis capabilities by interfacing with specific molecules 
that are involved in the growth and progression of the tumour. Small-molecule inhibitors and monoclonal 
antibodies are the main drugs that are currently in use in order to affect the specific biochemical pathways 
in cancer cells. However, likewise any other cancer therapies, targeted therapy has its own limitations. For 
instance, identifying a molecular target needed to begin treatment is one of those hardships. A specific 
molecule is crucial in this way of treatment. The other limitation is the toxicity that appears during the 
treatment, the same as in the case of traditional chemotherapy and radiotherapy. Furthermore, the cost 
of this therapy is significantly higher compared to classical treatments. However, the main obstacles are 
mechanisms of cancer drug resistance which are often developing in response to given drugs. In many 
cases, it makes further treatment impossible. This article is focusing on the limitations of molecularly 
targeted therapy.
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Introduction
The purpose of modern anticancer therapies is 
to overcome the difficulties resulting from insufficient 
knowledge of the tumour genome, its high diversity and 
instability. rapidly expanding knowledge of molecular 
biology and cancer genetics has provided us with tools 
that make personalized medicine possible. Molecularly 
targeted therapy focuses on the identification of molec-
ular changes on the level of a single patient, and also 
on optimization and individualization of treatment, as 
well as individual characteristics of the tumour micro-
environment [1–3].
The presuppositions of such therapy are to block the 
proliferation of cancer cells by interfering with specific 
molecules necessary for the successful tumour growth 
and development. Drugs are designed in such a way 
to affect a specific, targeted biochemical pathway [4]. 
The first and most crucial step in planning an effective 
treatment is to find specific molecules that serve as 
a molecular target. One of the methods is to identify 
proteins present in a tumour, but absent or exhibiting 
a decreased expression in normal, healthy cells. An-
other approach is to look for changed proteins that 
drive cancer progression. These can be fusion proteins 
located in altered cells — the cause of genetic instability. 
each cell has specific cell-surface receptors, which are 
responsible for activation of a response to extracellular 
stimuli. Often these proteins are used as the target of 
therapy because they show a relatively high frequency 
of mutation or overexpression [1–4].
Molecularly targeted cancer therapy
Molecular targets
An example of a protein that is a target of molecular 
therapy is vascular endothelial Growth Factor (veGF), 
one of the most important factors regulating the devel-
opment of tumour blood vessels, thereby modulating 
the process of angiogenesis. The angiogenesis process 
provides nutrients and oxygen for cancer cells, contrib-
uting to the formation and growth tumour. in addition, 
it allows the spread of cancer cells — veGF stimulates 
the secretion of more proteases, contributing to the 
degradation of the basal membrane. [5] inhibition of 
veGF makes it possible to arrest the growth of blood 
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vessels and cut off cancer cells from nutrients and 
oxygen [6]. There are two approaches used to disrupt 
veGF signalling, i.e. including ligand blockade and 
pharmacological blocking vascular endothelial Growth 
Factor receptor (veGFr).
Another example of a molecular target is epidermal 
Growth Factor receptor (eGFr). eGFr is a transmem-
brane glycoprotein that is overexpressed on the surface 
of numerous tumour cells. Binding of the receptor to 
the ligand leads to the activation of a signalling cas-
cade modulating proliferation, adhesion, migration, 
angiogenesis and metastasis. The use of monoclonal 
antibodies directed against eGFr causes binding and 
blocking of signalling pathways, which results in inhi-
bition of tumour growth development and also in the 
prevention of metastases [6].
The next protein used as the molecular target is 
Human epidermal Growth Factor receptor 2 (Her2), 
is characterized by the external activity of tyrosine 
kinase. Gene amplification and overexpression of this 
protein is identified in approximately 20% of breast 
cancer cases, it is also a negative prognostic factor. 
Her2 is a key mediator of cell growth and differentia-
tion. Her2-positive tumours show a higher degree of 
malignancy than other subtypes. inhibition or binding 
of this receptor may prevent the activation of signalling 
pathways, thus also the proliferation of the changed 
tissue [7].
An example of gene serving as a target in person-
alized therapy is B-raf Proto-Oncogene (BrAF). B-raf 
protein is a kinase from the rAF family of proteins and 
participates in intercellular signalling. BRAF mutations 
as BRAFV600E and BRAFV600K occurs with a  high 
frequency in various types of cancer, may be inherited 
or acquired during postnatal development. This kinase 
is part of the MAPK signalling pathway, which continu-
ous activation leads to increased proliferation, higher 
invasiveness and survival of cancer cells, and also 
increases the probability of metastasis. Modern drugs 
inhibit the activity of the altered protein by inhibiting 
this kinase [8].
Mechanism of action
Two action mechanisms of a targeted anti-cancer 
treatment can be distinguished. The first of these is 
blocking proliferation through the use of small molecule 
tyrosine kinase inhibitors (TKi) which causes impeding 
the activation of the signalling pathway by blocking the 
action of an abnormal protein (Tab. 1) [1, 2].
The second type of treatment uses monoclonal anti-
bodies that bind specifically to the target proteins, which 
leads to inhibition of their activity (Tab. 2). Through the 
use of genetic engineering, humanized and fully human 
monoclonal antibodies are produced and are used in 
the treatment of cancer [10].
Toxicity of drugs used in targeted therapy
Inhibitors of the Epidermal Growth Factor 
Receptor (EGFR)
epidermal growth factor receptor inhibitors are 
approved for treatment of early-stage cancers, such 
as non-small cell lung cancer, colorectal cancer, breast 
cancer, pancreatic cancer, head and neck cancer and 
squamous cell carcinoma. They include intravenous 
monoclonal antibody treatment or oral therapy with 
small tyrosine kinase inhibitors. eGFr is expressed in 
the structures of the skin, so inhibition is associated 
with a  number of adverse skin complications [11]. 
it is believed that this is related to the inhibition of eGFr 
in basal keratinocytes and hair follicles. They exhibit 
similar expression of eGFr as in cancer cells [12].
in clinical practice, one of the most commonly 
observed skin reactions is an acne-like eruption. 
it manifests itself with blister-like papules or pustules 
that occur in clusters. Aforementioned changes can 
cause itching, smarting, pain and irritation. in the first 
stage of treatment both, erythema and edema can be 
present. Papules may occur between the 2nd and 3rd 
week, and after about a month, persistent erythema, 
dryness and telangiectasia are commonly noted. in 
extreme cases, it is necessary to reduce the dose or 
completely terminate the treatment. Some patients 
notice an involution in post-treatment changes, but 
there are also cases in which severe and persistent 
acne-like reactions often develop [11, 13]. research 
regarding this subject reports a correlation between the 
occurrence of a rash and the effectiveness of treatment. 
it has been confirmed that acne-like changes in the 
treatment with the use of gefitinib and erlotinib may be 
an effective clinical indicator for predicting responses 
in patients with small cell lung cancer [14].
Another common side effect of eGFr inhibitors is 
Hand-Foot Syndrome or Palmar-Plantar erythrodyses-
thesia. in the case of sorafenib and sunitinib therapy, 
the intensity of these side effects is proportional to the 
dose [14]. Syndromes range from erythema, edema and 
burning, to hyperkeratosis. Those can significantly affect 
the well-being of the patient during therapy. Other skin 
complications include observable pathological changes 
in hair and nails, resulting in hair loss and brittleness, also 
nail brittleness, as well as discolouration or curling. [15]. 
Other side effects associated with eGFr inhibition include 
dry skin, pruritus, atrophy of the natural barrier protecting 
against infection, seborrheic dermatitis, subungual hem-
orrhage, photosensitivity or paronychia, manifested by 
purulent inflammation around the nails [11, 12].
Trastuzumab, a  monoclonal antibody directed 
against Her2, is mainly applied in breast cancer. The 
most common side effects are chills, fever, asthenia 
and nausea. However, cases of extensive and toxic 
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cardiovascular complications or even fatal pulmonary 
complications have also been reported. These severe 
events include primarily; dyspnea, pneumonia, lung 
infiltrates, edema, insufficiency or hypoxia. Usually, 
treatment termination can take place if initial symptoms 
indicating pulmonary complications occur [16, 17].
Inhibitors of B-RAF serine-threonine kinase
Skin lesions observed during treatment with eGFr 
inhibitors may also occur during targeted melanoma 
therapy. increased risk of skin complications during 
vemurafenib or dabrafenib therapy has been observed 
in the range of 8 to 36 weeks after administration of the 
first dose [18]. During BrAF inhibitors monotherapy, 
skin toxicity is observed in 92–99% of patients, the most 
common being acne-like lesions, maculopapular or 
exudative rashes [19]. in addition, painful wart-like le-
sions most commonly occur after 4 weeks of treatment. 
Another frequent side effect is the Hand-Foot Syndrome 
described earlier. Most patients taking BrAF inhibitors 
suffer from hypersensitivity to ultraviolet A  radiation 
(UvA). Side effects associated with exposure to UvA are 
manifested by severe sunburns, pain or blisters. Other 
side effects that occur during treatment of melanoma in-
clude alopecia, seborrheic dermatitis, follicular keratosis, 
or epidermal cysts [19, 20]. Treatment of skin lesions 
most often involves the use of antibiotics and corticoste-
roids, which carries additional toxicity to the patient. All 
described Dermatologic events (DeAs) exert enormous 
influence on the mental, social and physical health of 
patients and affect their overall quality of life [18].
Other possibly dangerous complications, occurring 
during treatment with drugs such as dabrafenib or ve-
murafenib are fever, skin lesions, hepatic toxicity and 
lymphopenia. Lymphopenia makes it difficult to initiate 
an immune response and thus leads to numerous 
infections. The late identification of infections caused 
by pathogens can lead to particularly severe and po-
tentially fatal diseases [21].
Inhibitors of Vascular Endothelial Growth Factor 
(VEGF)
in addition to skin complications, molecular targeted 
therapy can cause a number of other side effects. Tyrosine 
Kinase inhibitors like sorafenib, sunitinib, imatinib ora ax-
itinib may have side effects associated with hypothyroidism:
 — thyroid atrophy by inhibiting its vascularization,
 — preventing the binding of veGF to normal thy-
roid cells,
 — reducing the synthesis of thyroid hormones,
 — inhibition of iodine uptake,
 — sdrug-induced thyroid atrophy [22, 23].
Moreover, in 2010, thyroid dysfunction was de-
scribed in patients treated with gefitinib [23]. These 
events were related to its mechanism of action, as it 
affects a lot of tyrosine kinases and binds veGFr. The 
result of such interaction may be thyroid dysfunction 
occurring after less than a month of administrating the 
drug, it may have a place earlier than in the case of 
sorafenib or sunitinib [24].
veGF plays a  key role in the development of 
vascular blood vessels, which is why anti-angiogenic 
Table 1. examples of kinase inhibitors used in targeted therapy [8]
Mechanism of action Target Therapeutic indications
Dabrafenib Selectively binds B-raf protein. BrAF melanoma
vemurafenib Selectively binds to the BrAP ATP binding site. BrAF melanoma
Lapatinib reversibly blocks the phosphorylation of eGFr, erbB2, 
erK-1 and-2 and AKT kinases.
eGFr
Her2
breast cancer
erlotynib reversibly binds to the intracellular catalytic domain of 
the eGFr receptor. 
eGFr NSCLC,  
pancreatic cancer
Table 2. examples of antibodies used in targeted therapy [8]
Mechanism of action Target and type of  
monoclonal antibodies 
Therapeutic indications
Cetuximab Binds to the intracellular domain  
of eGFr.
eGFr 
chimeric igG1
colorectal cancer,  
HNSCC 
Bavacizumab inhibiting receptor activation  
by binds to veGF.
veGF humanize igG1 cervical cancer, NSCLC, 
glioblastoma, ovarian cancer, kidney 
cancer, colorectal cancer
Trastuzumab binds Her2 on the surface  
of tumor cells, bring cell-mediated 
cytotoxicity in relation to tumor  
cells that overexpress Her2.
Her2 humanize igG1 Stomach or esophageal 
adenocarcinoma, breast cancer 
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therapies focus on inhibiting this factor. Numerous 
inhibitors have been approved by the U.S. Food and 
Drug Administration (FDA) they show potential benefits 
but also cause significant dose-related complications. 
in 2011, the FDA withdrew the permission to use beva-
cizumab in case of treatment of breast cancer because 
the benefits did not outweigh the risks of the treatment 
[25, 26]. Due to the mechanism of action, the majority 
of adverse reactions resulting from anti-veGF therapy is 
associated with vascular disease. These include cardiac 
infarction, cerebral stroke, heart failure, hypertension, 
thromboembolism or proteinuria [25].
Hypertension is considered to be a frequent con-
sequence of undergoing veGF inhibitors therapy [25]. 
induction of hypertension may be connected with 
inhibition of nitric oxide production in endothelial cells. 
it usually is asymptomatic, but it can be a risk factor 
for cardiovascular disease or renal failure [27]. Another 
common consequence of using anti-angiogenic drugs 
is proteinuria, most likely caused by the inhibition of 
veGF paracrine signalling [25], or acute hypertension 
[12]. Proteinuria is associated with overproduction of 
abnormal proteins that can cause nephrotoxicity. The 
above side effects accompanying anti-veGF therapy 
may correlate with each other or may be a  result of 
long-term therapy. in the elderly, they are not a prog-
nostic factor [25].
There is also a  risk of arterial thromboembolic 
complications, as veGF inhibition may negatively affect 
blood dust and von willebrand factor, and consequently 
lead to the activation of the hemostasis system [12]. All 
agents directed against veGF are associated with an 
increased risk of bleeding [28, 29].
Anti-cancer drug resistance
Drug resistance can be one of the most significant 
limiting factors during anti-cancer treatment. The 
resistance may result from the adaptation of tumour 
cells caused by regular drug application or from the 
presence of pre-existing changes at the molecular level 
[30, 2]. Congenital cellular resistance is characterized 
by a lack of response to drugs from the beginning of 
their use. The acquired one, however, appears some-
time after the start of therapy, most often after 12 or 
18 months. Most patients develop resistance at one of 
the stages of treatment. There are many mutations and 
disorders that may result in the cell not being sensitive 
to targeted treatment [2, 31]. Asic K., in his work from 
2016, divided the resistance mechanisms into:
 — disturbances of drug penetration inside the cell 
— changes occurring in genes coding for tar-
get proteins,
 — addiction to the alternative signalling pathway 
— activation of a  protein that performs a  similar 
function, causing further growth of cancer cells,
 — changes leading to further activation of the target 
path — mutations or changes of genes encoding 
proteins below or above the target molecule,
 — replacement/imitation of the target function, 
 — activation at Multidrug resistance (MDr) [31].
Inhibitors of the Epidermal Growth Factor 
Receptor (EGFR)
in the case of treatment of non-small cell lung can-
cer (NSCLC) with erlotinib, all previously mentioned 
mechanisms have been observed, both congenital 
and acquired cellular resistance. During the treatment 
of colorectal cancer with cetuximab, in the case of 
congenital resistance, compensation of the eGFr func-
tion and changes in the regulation of the target signal 
pathway have been demonstrated. This resulted in the 
further activity of the eGFr molecule. in the example of 
acquired resistance, changes indicating contact with the 
drug have been shown [31, 32]. The primary problem in 
NSCLC therapy is the activation of alternative, parallel 
signalling pathways that cause the blockade created 
by the drug to be bypassed. One of the additional 
mechanisms of potential resistance is the activation of 
the insulin-like receptor 1 (iGFr1) [33].
Similarly, targeted therapy for Her2 overexpres-
sion in the treatment of breast cancer using monoclo-
nal antibodies may contribute to all of the previously 
mentioned mechanisms of cellular resistance. in the 
case of acquired resistance, MDr was excluded as 
well as replacement/imitation of the target function. 
when kinase inhibitors are used, further activation of 
the target signalling pathway and replacement/imi-
tation of the target functions by activation of another 
protein or MDr may also occur [31]. Trastuzumab 
is an example of a  drug that allows considerable 
clinical advances in the treatment of breast cancer. 
The impediments, however, is not fully understood. 
Changes in the cell cycle, DNA repair mechanisms, 
Pi3K signalling pathway, as well as inhibition of 
the extracellular protein domain or Her2 degrada-
tion are indicated. in the case of trastuzumab, the 
mechanism of impaired binding of the drug to the 
receptor may refer to the formation of a  truncated 
Her2 protein, devoid of the extracellular domain. re-
ceptor cloning by MUC4 glycoprotein has also been 
described. The loss of the PTeN suppressor gene 
(Phosphatase and Tensin Homolog), or excessive 
activation of the Pi3K-AKT pathway, results in the 
change of the signalling pathway into its alternative 
counterpart [33].
Inhibitors of B-RAF serine-threonine kinase
Mechanisms of congenital resistance occurring 
during treatment of melanoma with the BRAFV600E 
mutation using vemurafenib, include dependence on 
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alternative signalling pathways, further activation of 
the target pathway and imitation of the target function. 
in acquired resistance, it is also possible to make diffi-
cult contact with the drug by incomplete binding to the 
cancer cell. The use of sunitinib is associated with the 
occurrence of all the previously mentioned mechanisms 
of congenital cellular resistance, with the exception 
of the blockade of contact with the drug. Likewise, 
further activation of the target path was excluded from 
the acquired resistance [31]. in addition, it has been 
shown that by reducing tumour vasculature when using 
sunitinib, cancer cells acquiring resistance more often 
form distant metastases [34].
Under physiological conditions, erK signaling is 
regulated by feedback mechanisms to preserve homeo-
stasis of the body and normal cell growth. in tumors with 
the KRAS or BRAF mutation, this signaling disorders are 
often noticed and the phenomenon of overexpression of 
the path prompted researchers to use inhibitors of this 
erK signaling as a therapeutic agent - dabrafenib and 
vemurafenib. Treatment has shown that effectiveness 
correlates with the braking force of signaling. This is 
related to the rapid adaptation of the tumor to the in-
hibited pathway through mechanisms leading to rAF 
dimerization and the increased level of erK signaling. 
vemurafenib and dabrafenib require a monomeric rAF 
protein for inhibition. Therefore, when it is dimerized, 
the action of drugs is inhibited. Furthermore, tumor het-
erogeneity influence to the development of resistance 
to individual factors [35].
The cost of targeted therapies
The main premise of targeted therapies requires the 
use of state-of-the-art diagnostic technologies, blood 
and tissue banks, and the use of extended clinical 
knowledge, which significantly influences the cost of 
the final treatment. Drugs used in such therapies are 
designed to work on a specified biochemical pathway 
and require extensive trials, often limited to selected 
patient populations. Therefore, except for the biological 
barriers, which are often related to the mechanisms of 
resistance, also incomplete understanding of signaling 
pathways and further search for useful biomarkers, the 
widespread use of personalized medicine is limited by 
the economic barrier. There are various reasons why 
investors have doubts about the profitability of person-
alized treatment. One of the main sources of hesitation 
is the problem of identification of appropriate diagnostic 
technologies that would be both, effective and at the 
same time inexpensive [36].
expensive studies can be profitable only if, due to 
their high accuracy, they bring significant health benefits 
to well-identified target groups. Standard breast cancer 
treatment is based on chemotherapy and hormono-
therapy. in targeted treatment, other than the standard 
characteristics of a  tumor, such as size, lymph node 
metastases, or hormone levels, tests are performed 
in order to detect the expression of tumor genes and 
protein levels. An example is the Her2 receptor study 
to select candidates for trastuzumab treatment. it is rec-
ommended to apply either routine immunohistochem-
istry (iHC) or Fluorescent in situ Hybridization (FiSH). 
However, they differ in accuracy and efficiency, so 
researchers often have to do carry out both tests. Only 
patients with a Her2-positive result are classified for 
this therapy [37].
A relatively expensive study in targeted therapy at 
Her2 is a Histopathological analysis which uses anti-
bodies or Gene expression Profiling (GeP); as a tool 
for risk stratification. GeP includes gene analysis that 
uses either DNA microarray technology or polymerase 
chain reaction in real time (reverse Transcriptase PCr, 
rT-PCr) [37, 38]. Total cost of therapy for trastuzumeb 
of early-stage Her-positive breast cancer averages 
around $ 67,800 [39]. Treatment with trantuzumab 
with Her-positive stomach cancer is estimated at 
$ 90,000 a year [40].
FDA-approved vemurafenib, used in the treatment 
of metastatic melanoma in patients with the BrAF mu-
tation, is implemented instead of the standard dacar-
bazine treatment. Curl et al. compared the cost-effec-
tiveness of both treatments. it was shown that the cost 
of using vemurafenib is inadequate to its results [41].
Comparative analysis indicates that the overall 
cost of targeted therapy may outweigh the benefits of 
the treatment. in 2011, the majority of targeted drugs 
approved by the FDA, assuming a 12-month treatment, 
required a cost of $ 20,000, which resulted in insurance 
companies starting to withhold their expenses for treat-
ment. The costs of targeted therapy fell completely on 
the patient, which in many cases led to stressful situ-
ations resulting from the loss of financial liquidity an 
example may be bevacizumab approved for treatment, 
among others colorectal cancer, NSCLC or ovarian 
cancer. The annual cost of the treatment is estimated 
around $ 50,000, which in some cases can amount to 
$ 100,000. Finally, the monoclonal antibody was with-
drawn from the treatment of breast cancer due to proven 
ineffectiveness compared to standard therapy, while the 
cost of treating the patient for one year could be as high 
as $ 500,000. Another drug, the use of which requires 
large financial outlays is cetuximab, approved for the 
treatment of among others NSCLC. Patient’s therapy 
with its use costs about $ 800,000 a year. even if there 
are funds for treatment, this does not ensure survival, 
but it may have many side effects that adversely affect 
the patient’s well-being [40]. Another problem that con-
sumes large financial outlays is the costs of mitigation or 
treatment of side effects. in contrast to diagnostics, they 
are not included in the estimated cost of therapy [41].
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conclusions
Molecular Targeted Therapy is one of the mod-
ern tools used in the fight against such cancers as 
melanoma, breast cancer or colorectal cancer. The 
condition for its use is accurate diagnostics which 
enables the characterization of cancer cells. The 
most important element of this therapy is to find 
a molecular target. Novel, highly reliable markers for 
targeting cancer cells with a specific phenotype are 
still being sought.
in most patients, drug resistance appears after 
a certain time, despite the initial effectiveness of the im-
plemented therapy. After the acquisition of resistance, it 
seems almost impossible to overcome the mechanisms 
allowing cancer cells to further undisturbed proliferation. 
Most often in this case the treatment with personalized 
therapy is completed and the patient is treated with 
standard methods. There have also been attempts to 
circumvent resistance mechanisms through the use of 
combination therapies, but this is always associated 
with increased costs of treatment.
Another problem in the use of personalized therapy 
is high toxicity. Although the effect of therapy is target-
ed, it still affects normal cells. Some cells in the body 
show expression of molecules that serve as a molecular 
target, but not as pathological as in cancer cells. For 
this reason, drugs directed against eGFr or Her2 most 
often cause dangerous skin changes, anti-angiogenic 
drugs, and cardiovascular complications. The increase 
of side effects is associated with the reduction in the 
dose of the drug or, in extreme cases, termination of 
therapy. Mechanisms of resistance and toxicity of ther-
apy chiefly reduce its effectiveness.
The additional factor is the costs of diagnostics, 
medicines and combating side effects. They predom-
inantly contribute to the unprofitability of treatment. 
if the effects are inadequate to the incurred costs 
and they additionally reduce the patient’s quality of 
life, the drugs are not approved, and even though 
they were previously registered, they are removed 
from circulation.
The limitations of molecular targeted therapy are 
in many cases greater than with standard anti-cancer 
therapies. Meeting the requirements for reducing side 
effects and costs with simultaneously higher efficacy 
would require using molecules that are found on 
cancer cells as a molecular target, but are absent on 
normal cells (Fig. 1). expanding our knowledge of 
the resistance mechanisms and signaling pathways 
in tumors would increase the chance of success for 
targeted therapy. it is equally important to look for new 
methods of drug production and diagnostic tests that 
would minimize the cost of treatment.
Reduction cost 
of therapy
Searching for  
molecular targets
Overcoming of 
resistance mechanisms
Reduction 
of toxicity
Figure 1. Perspectives for Molecularly targeted therapy
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